항고혈압 약물 3종 복합제에 대한 선진 외국의 임상자료 심사사례 비교
Comparison of Clinical Development and Evaluation of Triple Antihypertensive Therapy in Advanced Foreign Countries
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Fixed drug combinations are formulations containing two or more active ingredients in a single dosage form. Such combination therapies are commonly applied to improve efficacy, reduce adverse events and replace coadministration, etc. National and international guidelines for hypertension treatment recommend addition of other classes of antihypertensive drugs rather than incremental dose of mono-therapy, when blood pressure is not adequately controlled. Thus, many dual combinations of antihypertensive drugs have been approved and pharmaceutical companies are recently interested in developing antihypertensive triple combinations. Clinical trial designs for the fixed combinations are various depending on the target patients, dosage and clinical endpoints. Thereby, further discussions for the clinical trials of antihypertensive triple therapies are required regarding the indication claimed. Conclusion: This article provides a review for the assessment of the label and medical reports of the clinical trials on antihypertensive triple therapies in advanced foreign countries.
Abstract
Background: Fixed drug combinations are formulations containing two or more active ingredients in a single dosage form. Such combination therapies are commonly applied to improve efficacy, reduce adverse events and replace coadministration, etc. National and international guidelines for hypertension treatment recommend addition of other classes of antihypertensive drugs rather than incremental dose of mono-therapy, when blood pressure is not adequately controlled. Thus, many dual combinations of antihypertensive drugs have been approved and pharmaceutical companies are recently interested in developing antihypertensive triple combinations. Clinical trial designs for the fixed combinations are various depending on the target patients, dosage and clinical endpoints. Thereby, further discussions for the clinical trials of antihypertensive triple therapies are required regarding the indication claimed. Conclusion: This article provides a review for the assessment of the label and medical reports of the clinical trials on antihypertensive triple therapies in advanced foreign countries.
참고문헌 (24)
- Chobanian AV, "Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure", Hypertension, 42(6), pp.1206~1252 (2003)
- Mancia G, "Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European Society of Cardiology (ESC)", J Hypertens, 25, pp.1105~1187 (2007)
- Bae JH, "Korean Hypertension Treatment Guidelines", The Korean Society of Hypertension, 5(15), pp.27~34 (2004)
- 성예나, "고혈압 환자의 혈압강하제 처방양상- 외래 처방전을 중심으로", 한국임상약학회지, 19(2), pp.167~179 (2009), 한국임상약학회
- Dahlof B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial", Lancet, 366(9489), pp.895~906 (2005)
- Bangalore S, "Fixeddose combinations improve medication compliance: a meta-analysis", Am J Med, 120, pp.713~719 (2007)
- "Guideline on clinical development of fixed combination medical products", EMA, ~ (2009)
- "Guideline on clinical investigation of medicinal products in the treatment of hypertension", EMA, ~ (2011)
- "Principles for clinical evaluation of new antihypertensive drugs", ICH, ~ (2000)
- 박현주, "고혈압치료제의 임상시험평가지침 연구", Translational and Clinical Pharmacology, 17(2), pp.124~138 (2009), 대한임상약리학회
- "Guideline on the cardiovascular drug combination", KFDA, ~ (2011)
- "Consideration for drugs combination development-focus on antihypertensive drugs", KFDA, 2009
- "US label information, medical review and clinical pharmacology review of Exforge HCT®(amlodipine, valsartan, hydrochlorothiazide) Tablet", US, 2009
- Summary of Product Characteristics and assessment report of Exforge HCT film-coated tablets, , EMA, ~ (2009)
- Calhoun DA, "Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial", Hypertension, 54, pp.32~39 (2009)
- US label information, "medical review and clinical pharmacology review of Tribenzor®(olmesartan medoxomil, amlodipine, hydrochlorothiazide) Tablet", US, 2010
- "Summary of Product Characteristics of Sevikar HCT filmcoated tablets", UK, ~ (2013)
- Oparil S, "Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week,parallel-group study", Clin Ther, 32, pp.1252~1269 (2010)
- Volpe M, "Efficacy and safety of triple antihypertensive therapy with the olmesartan", amlodipine, Clin Drug Investig, pp.2012, 32(10)[DOI]
- Kereiakes DJ, "Olmesartan", amlodipine, Cardiovasc Diabetol, pp.2012, 11[DOI]
- De la Sierra A, "Blood pressure control with angiotensin receptor blocker-based three-drug combinations", key trials. Adv Ther, 29(5), pp.401~415 (2012)
- "Public disclosure about drug review information of SevikaHCT", KFDA, ~ (2012)
- "Summary of Product Characteristics of Sevikar film-coated tablets", UK, ~ (2012)